Literature DB >> 18312365

Factor XI deficiency.

K Gomez1, P Bolton-Maggs.   

Abstract

Although factor XI (FXI) deficiency has a particularly high incidence in Ashkenazi Jews, it is now frequently diagnosed in other ethnic groups. This review gives an overview of the basic pathophysiology, clinical manifestations, and management of FXI deficiency. The correlation between FXI levels and the bleeding phenotype is much less clear than in the haemophilias, and consequently the bleeding risk can be difficult to predict. Two well-characterized mutations in the F11 gene are responsible for the majority of Jewish cases, but new mutations are becoming increasingly recognized. The publication of the crystal structure has greatly enhanced our understanding of the structure-function relationship in FXI. The impact of recent studies on our understanding of the role of FXI in coagulation is discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312365     DOI: 10.1111/j.1365-2516.2008.01667.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  22 in total

1.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

Review 2.  Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Authors:  Becky Woodruff; Bruce Sullenger; Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

3.  Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures.

Authors:  Giuseppe Tagariello; Paolo Radossi; Roberta Salviato; Milena Zardo; Lucia De Valentin; Marco Basso; Giancarlo Castaman
Journal:  Blood Transfus       Date:  2016-07-22       Impact factor: 3.443

4.  Successful perioperative management in a patient with factor XI deficiency.

Authors:  Margaret L McCarthy; Sarah M Ordway; Ryan M Jones; Jeremy G Perkins
Journal:  BMJ Case Rep       Date:  2018-02-21

5.  Revisiting the molecular epidemiology of factor XI deficiency: nine new mutations and an original large 4qTer deletion in western Brittany (France).

Authors:  Paul Guéguen; Angélique Chauvin; Sylvia Quémener-Redon; Brigitte Pan-Petesch; Claude Férec; Jean-François Abgrall; Cédric Le Maréchal
Journal:  Thromb Haemost       Date:  2011-12-08       Impact factor: 5.249

6.  Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.

Authors:  Rami A Al-Horani; Elnaz Parsaeian; Mariam Mohammad; Madhusoodanan Mottamal
Journal:  Chem Biol Drug Des       Date:  2022-04-11       Impact factor: 2.873

7.  Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.

Authors:  Rami A Al-Horani; Pooja Ponnusamy; Akul Y Mehta; David Gailani; Umesh R Desai
Journal:  J Med Chem       Date:  2013-01-28       Impact factor: 7.446

8.  Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  J Med Chem       Date:  2014-05-29       Impact factor: 7.446

9.  A patient with a prolonged activated partial thromboplastin time and a deep intracerebral haemorrhage.

Authors:  Roger K Schindhelm; Mariëlle J Wondergem; Joke Admiraal; Gert Nap; Edwin Ten Boekel; Lahcen Hani
Journal:  Case Rep Neurol       Date:  2012-08-22

10.  Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.

Authors:  Malaika D Argade; Akul Y Mehta; Aurijit Sarkar; Umesh R Desai
Journal:  J Med Chem       Date:  2014-04-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.